Jintropin 100 IU 10 vials of 3.7 mg/10 iu

Jintropin from GeneScience is a recombinant growth hormone containing 191 amino acids. It is produced from genetically modified bacterial cultures and is fully bioavailable. It is manufactured by the powerful Chinese pharmaceutical company GeneScience Pharmaceuticals Co. It is distinguished by its high quality, reliability, and compliance with international certifications. It is a leading seller in the sports and hormonal supplement industry.

Effects of taking Jintropin

1. increases physical strength during exercise;
2. optimizes energy metabolism and the functioning of the cardiovascular system;
3. strengthens the immune system and overall health;
4. improves brain function during mental stress;
5. accelerates tissue regeneration, has a rejuvenating effect;
6. improves the condition of the skin;
7. accelerates the production of red blood cells;
8. promotes rapid muscle mass gain;
9. strengthens bones and joints;
10. reduces the amount of subcutaneous fat during the drying period.

The only positive benefit of somatotropin (compared to other anabolic agents) for athletes is that the strength and muscle size achieved with it typically do not diminish after the end of the course. This is due to the increased number of muscle cells. Due to this, many athletes can continue progressing for months after stopping somatotropin use. Another benefit of somatotropin is that frequent injections into the same area can lead to the "burning" of fat deposits in that area, potentially leading to the development of soft tissue abscesses.

Medical indications for taking Jintropin

• replacement therapy for adults with severe growth hormone deficiency.
• The development of growth hormone deficiency in adulthood. Patients with severe growth hormone deficiency associated with multiple hormonal deficiencies due to known hypothalamic or pituitary pathology, as well as patients with a deficiency of at least one pituitary hormone except prolactin, should undergo appropriate dynamic testing to determine the presence or absence of growth hormone deficiency.
• For patients with growth hormone deficiency that developed in childhood (due to hereditary, genetic, acquired, or unknown causes), a repeat test for hormone secretory capacity should be performed after the end of longitudinal growth. For patients with a high probability of permanent growth hormone deficiency (e.g., due to hereditary causes or secondary growth hormone deficiency due to hypothalamic-pituitary disease or stroke), the mean deviation of insulin-like growth factor type 1 (IGF-1) is less than -2 without growth hormone treatment.

For other patients, an IGF-1 assay and one growth hormone stimulation test are required.

Use and dosage of Jintropin

In order to achieve the improvements described earlier, it is necessary to adhere to the correct intake scheme - interval to achieve each task.

Before using this medication, consult a doctor. They will be able to assess your health, determine any contraindications, and prescribe the most appropriate course of treatment to avoid any potential adverse effects.

Side effects

The most common side effects of somatotropin medications are the risk of developing diabetes and possible hypothyroidism. The rare occurrence of antibodies to somatotropin is negligible. As for increased growth of individual organs and limbs, these, if they occur, occur pre-pubertal or post-pubertal, but only in individuals with hypogonadism.

People suffering from endogenous hypersecretion may develop acromegaly after puberty. Bones become thicker and wider, but not longer. There is increased growth of the hands and feet, as well as enlargement of the facial features due to the enlargement of the lower jaw and nose. The heart muscle and kidneys may increase in size and mass. This often results in general weakness, diabetes, heart disease, and premature death.

When using somatotropin preparations in sports, it should also be taken into account that their isolated use has minimal effectiveness.

Contraindications

Hypersensitivity to the active substance or any of the excipients.

Somatropin should not be prescribed if there are any signs of tumor activity. Intracranial tumors should be inactive, and antitumor therapy should be completed before initiating growth hormone therapy. If there are any signs of tumor growth, treatment should be discontinued.

Somatin should not be used for growth promotion in children with closed epiphyseal growth plates.

Treatment with Somatin is contraindicated in patients in acute critical condition due to complications of open heart surgery, abdominal surgery, multiple trauma, acute respiratory failure, or other similar conditions (for information on patients receiving replacement therapy, see the section “Special instructions for use”).

Somatropin is contraindicated in patients with active proliferative or severe nonproliferative diabetic retinopathy.

Somatropin is contraindicated in children with Prader-Willi syndrome, severe obesity, or severe respiratory impairment.

In children with chronic kidney disease, somatropin treatment should be discontinued when kidney transplantation is performed.

What to avoid

During the course, it's important to monitor your thyroid function. Jintropin is contraindicated for people with diabetes, glucose intolerance, or hypothyroidism. Never exceed the recommended dosage, as this can lead to serious hormonal changes and severe side effects.

Interaction with other medicinal products and other types of interactions.

Concomitant use with glucocorticoids may inhibit the growth-promoting effect of somatropin-based medications. Therefore, the growth of patients receiving glucocorticoid therapy should be closely monitored to assess the potential impact of glucocorticoid use on growth.

Growth hormone reduces the conversion of cortisone to cortisol and may uncover previously undiagnosed central hypoadrenalism or render low-dose glucocorticoid replacement therapy ineffective.

Somatropin is an inducer of cytochrome P450 (CYP) activity, which may lead to decreased plasma concentrations and, consequently, decreased efficacy of drugs metabolized by CYP3A, such as sex hormones, corticosteroids, cyclosporine, and anticonvulsants. The clinical significance of this is unknown.

For more information on diabetes mellitus and thyroid dysfunction, see the section “Special instructions for use”, and for oral estrogen replacement therapy, see the section “Dosage and administration”.